[{"id":"976f7440-4689-49dd-a48e-afbffc7bdabd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04660929","created_at":"2021-01-19T20:42:33.281Z","updated_at":"2024-07-02T16:35:10.054Z","phase":"Phase 1","brief_title":"CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors","source_id_and_acronym":"NCT04660929","lead_sponsor":"Carisma Therapeutics Inc","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • CT-0508"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 02/02/2021","start_date":" 02/02/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-11"},{"id":"32402300-ed12-444a-8c26-2796065462cb","acronym":"Micros","url":"https://clinicaltrials.gov/study/NCT03737435","created_at":"2021-01-18T18:18:22.782Z","updated_at":"2024-07-02T16:35:13.275Z","phase":"","brief_title":"Tumor Microenvironment in Patients With Localized Osteosarcoma Treated With Mifamurtide: a Translational Study","source_id_and_acronym":"NCT03737435 - Micros","lead_sponsor":"Istituto Ortopedico Rizzoli","biomarkers":" PD-L1 • CD68","pipe":"","alterations":" ","tags":["PD-L1 • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mepact (mifamurtide)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-03-22"},{"id":"1f8bf35c-c5e0-487a-987a-3fa6416c7152","acronym":"","url":"https://clinicaltrials.gov/study/NCT05967416","created_at":"2023-08-01T16:10:21.784Z","updated_at":"2024-07-02T16:35:26.181Z","phase":"Phase 1","brief_title":"Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT05967416","lead_sponsor":"SIRPant Immunotherapeutics, Inc.","biomarkers":" SIRPA","pipe":"","alterations":" ","tags":["SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SIRPant-M (RB-1355)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-12-14"}]